Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.85 | N/A | -3.41% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.85 | N/A | -3.41% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current performance but highlighted their commitment to addressing operational issues. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
Future plans were discussed, but no specific guidance was provided.
Crinetics Pharmaceuticals reported a loss that was slightly worse than expected, which contributed to a modest decline in the stock price. Investors may be concerned about the lack of revenue information and the absence of guidance for future performance. The stock's reaction reflects cautious sentiment in light of the company's current challenges and management's defensive tone.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STRYKER CORP
May 1, 2023